123 related articles for article (PubMed ID: 35488333)
1. Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19.
So ACP; Karampera C; Khan M; Russell B; Moss C; Monroy-Iglesias MJ; Thillai K; Josephs DH; Pintus E; Rudman S; Van Hemelrijck M; Dolly S; Enting D
BMC Urol; 2022 Apr; 22(1):71. PubMed ID: 35488333
[TBL] [Abstract][Full Text] [Related]
2. The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer Centre.
Russell B; Moss C; Tsotra E; Gousis C; Josephs D; Enting D; Karampera C; Khan M; Roca J; Sita-Lumsden A; Owczarczyk K; Wylie H; Haire A; Smith D; Zaki K; Swampillai A; Lei M; Manik V; Michalarea V; Kristeleit R; Mera A; Sawyer E; Flanders L; De Francesco I; Papa S; Ross P; Spicer J; Dann B; Jogia V; Shaunak N; Kristeleit H; Rigg A; Montes A; Van Hemelrijck M; Dolly S
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053432
[TBL] [Abstract][Full Text] [Related]
3. Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first wave.
Russell B; Moss C; Monroy-Iglesias M; Roberts G; Dickinson H; Haire K; Innes K; Mulji-Shah B; Castell F; Al-Salihi O; Lei M; Francis A; Dann B; Jogia V; Hamid H; Challacombe B; Simo R; Fraser S; Gousis C; Sawyer E; Tsotra E; Roca J; Khan M; Josephs D; Enting D; Van Hemelrijck M; Harris V; Dolly S
Br J Cancer; 2022 Oct; 127(7):1289-1295. PubMed ID: 35840733
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.
Crolley VE; Hanna D; Joharatnam-Hogan N; Chopra N; Bamac E; Desai M; Lam YC; Dipro S; Kanani R; Benson J; Wilson W; Fox TA; Shiu KK; Forster M; Bridgewater J; Hochhauser D; Khan K
Ther Adv Med Oncol; 2020; 12():1758835920971147. PubMed ID: 33178336
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 pandemic impact on uro-oncological disease outcomes at an Italian tertiary referral center.
Oderda M; Soria F; Rosi F; Calleris G; Mazzoli S; Giordano A; Pizzuto G; Marquis A; De Bellis M; Vitiello F; Vercelli E; Peretti F; Montefusco G; Gontero P
World J Urol; 2022 Jan; 40(1):263-269. PubMed ID: 34562122
[TBL] [Abstract][Full Text] [Related]
6. The provision of neuro-oncology and glioma neurosurgery during the SARS-CoV-2 pandemic: a single national tertiary centre experience.
Amoo M; Horan J; Gilmartin B; Nolan D; Corr P; MacNally S; Husien MB; Javadpour M
Ir J Med Sci; 2021 Aug; 190(3):905-911. PubMed ID: 33155104
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with adjuvant systemic anti-cancer treatment discontinuation for early breast cancer during the COVID-19 pandemic.
Gatfield ER; Bataineh A; El Kurdi B; Mukesh MB; Loo SW
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13668. PubMed ID: 35950493
[TBL] [Abstract][Full Text] [Related]
8. Thirty-day mortality after systemic anticancer treatment as a real-world, quality-of-care indicator: the Northland experience.
Ang E; Newton LV
Intern Med J; 2018 Apr; 48(4):403-408. PubMed ID: 28872748
[TBL] [Abstract][Full Text] [Related]
9. Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre.
Khoja L; McGurk A; O'Hara C; Chow S; Hasan J
Eur J Cancer; 2015 Jan; 51(2):233-40. PubMed ID: 25500146
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in the Covid-19 era: the patient's perception.
Hennessy MA; Linehan A; Cowzer D; Coyne ZL; Fitzpatrick O; Barrett F; Ni Dhonaill R; Hennessy BT; Grogan L; Morris PG; Breathnach OS
Ir J Med Sci; 2021 Nov; 190(4):1303-1308. PubMed ID: 33449325
[TBL] [Abstract][Full Text] [Related]
12. Urological cancer patients receiving treatment during COVID-19: a single-centre perspective.
Williams ST; El Badri S; Hussain SA
Br J Cancer; 2021 Apr; 124(9):1513-1515. PubMed ID: 33558714
[TBL] [Abstract][Full Text] [Related]
13. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
Wallington M; Saxon EB; Bomb M; Smittenaar R; Wickenden M; McPhail S; Rashbass J; Chao D; Dewar J; Talbot D; Peake M; Perren T; Wilson C; Dodwell D
Lancet Oncol; 2016 Sep; 17(9):1203-16. PubMed ID: 27599138
[TBL] [Abstract][Full Text] [Related]
14. [Urologic cancer care during the first wave of the COVID-19 pandemic : Role of federal cancer registration in Germany].
Bolenz C; Vogel T; Morakis P; Mayr R; Marx M; Burger M
Urologe A; 2021 Mar; 60(3):291-300. PubMed ID: 33559692
[TBL] [Abstract][Full Text] [Related]
15. Uro-oncology in times of COVID-19: The available evidence and recommendations in the Indian scenario.
Narain TA; Gautam G; Seth A; Panwar VK; Rawal S; Dhar P; Talwar HS; Singh A; Jaipuria J; Mittal A
Indian J Cancer; 2020; 57(2):129-138. PubMed ID: 32445315
[TBL] [Abstract][Full Text] [Related]
16. Lessons from the coronavirus disease 2019 pandemic: Will virtual patient management reshape uro-oncology in Germany?
Rodler S; Apfelbeck M; Stief C; Heinemann V; Casuscelli J
Eur J Cancer; 2020 Jun; 132():136-140. PubMed ID: 32361628
[TBL] [Abstract][Full Text] [Related]
17. Impact of the COVID-19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan.
Monroy-Iglesias MJ; Rai S; Mistretta FA; Roberts G; Dickinson H; Russell B; Moss C; De Berardinis R; Ferro M; Musi G; Brown C; Nair R; Thurairaja R; Fernando A; Cathcart P; Khan A; Dasgupta P; Malde S; Hadijpavlou M; Dolly S; Haire K; Tagliabue M; de Cobelli O; Challacombe B; Van Hemelrijck M
BJUI Compass; 2022 Jul; 3(4):277-286. PubMed ID: 35783588
[TBL] [Abstract][Full Text] [Related]
18. Has the COVID-19 Pandemic Increased Mortality Among Patients with Cancer Receiving Systemic Anticancer Treatments?
Demirci A; Bilir C; Cakir E; Gulbagci B; Hacibekiroglu I; Varim C
J Coll Physicians Surg Pak; 2021 Jan; 31(1):S66-S70. PubMed ID: 34530531
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of mortality within 30 days of systemic anticancer therapy and comparison with a previous audit at an Australian Regional Cancer Centre.
Zimbwa B; Gilbar PJ; Davis MR; Kondalsamy-Chennakesavan S
J Oncol Pharm Pract; 2022 Jul; 28(5):1077-1084. PubMed ID: 33990165
[TBL] [Abstract][Full Text] [Related]
20. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.
Wallis CJD; Novara G; Marandino L; Bex A; Kamat AM; Karnes RJ; Morgan TM; Mottet N; Gillessen S; Bossi A; Roupret M; Powles T; Necchi A; Catto JWF; Klaassen Z
Eur Urol; 2020 Jul; 78(1):29-42. PubMed ID: 32414626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
